M&A Deal Summary |
|
|---|---|
| Date | 2025-08-20 |
| Target | Mural Oncology |
| Sector | Life Science |
| Buyer(s) | XOMA Royalty |
| Deal Type | Add-on Acquisition |
| Deal Value | 36M USD |
| Advisor(s) | Lucid Capital Markets (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 13 |
| Revenue | 10M USD (2024) |
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty is based in Emeryville, California.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 5 |
| Sector: Life Science M&A | 5 of 5 |
| Type: Add-on Acquisition M&A Deals | 5 of 5 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2025 M&A | 4 of 4 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-08-04 |
Lava Therapeutics
Utrecht, Netherlands Lava Therapeutics focused on applying its expertise in gamma-delta T cell engagers (TCEs) to transform cancer therapy. The company's platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells that have the ability to trigger the activity of immune cells of both the innate and adaptive immune system. Its gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. Lava Therapeutics was founded in 2016 and is based in Utrecht, Netherlands. |
Buy | - |
